<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01502423</url>
  </required_header>
  <id_info>
    <org_study_id>M11-964</org_study_id>
    <secondary_id>2011-003953-25</secondary_id>
    <nct_id>NCT01502423</nct_id>
  </id_info>
  <brief_title>A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab</brief_title>
  <official_title>A Multicenter, Randomized, Single-Blind Crossover Study of the Safety and Tolerability of Two Adalimumab Formulations in Adult Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare injection site pain levels between current Humira® formulation versus
      a new formulation of Humira in patients with Rheumatoid Arthritis (RA), who are either
      currently on a stable dose (minimum six consecutive doses) of on-label Humira or biological
      naïve who will be prescribed on-label Humira as treatment for their Rheumatoid Arthritis. The
      study is being conducted in three countries, Australia (3 sites), Canada (2 sites), and
      Germany (2 sites).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      61 participants were randomized, and 60 received at least one dose of the study drug. One
      participant, who was randomized to the New formulation of adalimumab/Current formulation
      adalimumab arm of the study, discontinued from the study and never received study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Injection Site Pain on a Visual Analogue Scale (VAS)</measure>
    <time_frame>Immediately after injection.</time_frame>
    <description>The primary response variable is participant's immediate pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm), with 0 representing no pain and 10 representing the worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Injection Site Pain on a Visual Analogue Scale (VAS)</measure>
    <time_frame>15 minutes post injection</time_frame>
    <description>The secondary response variable is participant's pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm) recorded 15 minutes after the injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale</measure>
    <time_frame>10 minutes and 30 minutes after injection</time_frame>
    <description>Hemorrhage/petechiae (bleeding/spots of bleeding underneath the skin) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With no Erythema in the Draize Scale</measure>
    <time_frame>10 minutes and 30 minutes after injection</time_frame>
    <description>Erythema (redness) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With no Edema in the Draize Scale</measure>
    <time_frame>10 minutes and 30 minutes after injection</time_frame>
    <description>Edema (swelling) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With no Pruritus in the Draize Scale</measure>
    <time_frame>10 minutes and 30 minutes after injection</time_frame>
    <description>Pruritus (itching) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. Serious adverse events were collected from the time that participant signed the informed consent.</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Current formulation adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New formulation of adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)</description>
    <arm_group_label>Current formulation adalimumab</arm_group_label>
    <arm_group_label>New formulation of adalimumab</arm_group_label>
    <other_name>Humira</other_name>
    <other_name>ABT-D2E7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject age 18 years or older, who requires Humira 40 mg SC every other
             week (eow) or every week (ew) for the treatment of rheumatoid arthritis, in accordance
             with the local Humira label.

          -  Subject must be a current, on-label user of Humira who rates his/her average Humira
             injection site related pain as at least 3 cm on a pain Visual Analogue Scale and has
             had at least 6 consecutive doses of Humira prior to Screening, or a biologic naïve
             subject who requires initiation of on-label treatment with Humira.

          -  Subject has diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised ACR
             classification criteria or the ACR/EULAR 2010 criteria,

          -  Female subjects are either not of childbearing potential, defined as postmenopausal
             for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral
             oophorectomy and/or hysterectomy), or are practicing at least one method of birth
             control throughout the study and for at least 70 days after the last dose of study
             drug.

          -  All female subjects of childbearing potential must have a negative test for pregnancy
             on a serum sample at Screening and prior to study drug dosing on a urine sample
             obtained at Visit 1.

        Exclusion Criteria:

          -  Subject has been treated with any investigational drug of a chemical or biologic
             nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug
             prior to Visit 1.

          -  Any infection(s) requiring treatment with intravenous (IV) anti-infectives within 30
             days prior to Visit 1 or oral anti-infectives within 14 days prior to Visit 1.

          -  Prior exposure to natalizumab (Tysabri®) or efalizumab (Raptiva®).

          -  Known hypersensitivity to adalimumab or its excipients.

          -  History of demyelinating disease (including myelitis) or neurologic symptoms
             suggestive of demyelinating disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Payne, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63354</name>
      <address>
        <city>Malvern East</city>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63355</name>
      <address>
        <city>Maroochydore</city>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63353</name>
      <address>
        <city>Shenton Park</city>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 67105</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 64122</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 63356</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 69242</name>
      <address>
        <city>Ostseebad Damp</city>
        <zip>24351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA-approved. Please see US prescribing information for approved uses.</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2011</study_first_posted>
  <results_first_submitted>November 7, 2013</results_first_submitted>
  <results_first_submitted_qc>January 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2014</results_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>On label Humira users</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant, who was randomized to the New formulation of adalimumab/Current formulation adalimumab arm, discontinued before receiving any study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Current Formulation Adalimumab/New Formulation of Adalimumab</title>
          <description>First dose with 40 mg of current formulation of adalimumab in a pre-filled syringe and second dose with 40 mg of new formulation of adalimumab in a pre-filled syringe.</description>
        </group>
        <group group_id="P2">
          <title>New Formulation of Adalimumab/Current Formulation Adalimumab</title>
          <description>First dose with 40 mg of new formulation of adalimumab in a pre-filled syringe and second dose with 40 mg of current formulation of adalimumab in a pre-filled syringe.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All analyses were based on the cITT population, which included all subjects who were randomized and completed both periods and received study drug in both periods of the study (N = 60).</population>
      <group_list>
        <group group_id="B1">
          <title>Current Formulation Adalimumab/New Formulation of Adalimumab</title>
          <description>First dose with 40 mg of current formulation of adalimumab in a pre-filled syringe and second dose with 40 mg of new formulation of adalimumab in a pre-filled syringe.</description>
        </group>
        <group group_id="B2">
          <title>New Formulation of Adalimumab/Current Formulation Adalimumab</title>
          <description>First dose with 40 mg of new formulation of adalimumab in a pre-filled syringe and second dose with 40 mg of current formulation of adalimumab in a pre-filled syringe.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="11.56"/>
                    <measurement group_id="B2" value="54.4" spread="14.11"/>
                    <measurement group_id="B3" value="56.4" spread="12.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Injection Site Pain on a Visual Analogue Scale (VAS)</title>
        <description>The primary response variable is participant's immediate pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm), with 0 representing no pain and 10 representing the worst possible pain.</description>
        <time_frame>Immediately after injection.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Current Formulation Adalimumab</title>
            <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
          </group>
          <group group_id="O2">
            <title>New Formulation of Adalimumab</title>
            <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Injection Site Pain on a Visual Analogue Scale (VAS)</title>
          <description>The primary response variable is participant's immediate pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm), with 0 representing no pain and 10 representing the worst possible pain.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.72"/>
                    <measurement group_id="O2" value="0.9" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Injection Site Pain on a Visual Analogue Scale (VAS)</title>
        <description>The secondary response variable is participant's pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm) recorded 15 minutes after the injection.</description>
        <time_frame>15 minutes post injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Current Formulation Adalimumab</title>
            <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
          </group>
          <group group_id="O2">
            <title>New Formulation of Adalimumab</title>
            <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Injection Site Pain on a Visual Analogue Scale (VAS)</title>
          <description>The secondary response variable is participant's pain of injection on a visual analogue scale (VAS) of 0 to 10 (cm) recorded 15 minutes after the injection.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.61"/>
                    <measurement group_id="O2" value="0.4" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale</title>
        <description>Hemorrhage/petechiae (bleeding/spots of bleeding underneath the skin) was assessed.</description>
        <time_frame>10 minutes and 30 minutes after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Current Formulation Adalimumab</title>
            <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
          </group>
          <group group_id="O2">
            <title>New Formulation of Adalimumab</title>
            <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale</title>
          <description>Hemorrhage/petechiae (bleeding/spots of bleeding underneath the skin) was assessed.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.7"/>
                    <measurement group_id="O2" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With no Erythema in the Draize Scale</title>
        <description>Erythema (redness) was assessed.</description>
        <time_frame>10 minutes and 30 minutes after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Current Formulation Adalimumab</title>
            <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
          </group>
          <group group_id="O2">
            <title>New Formulation of Adalimumab</title>
            <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With no Erythema in the Draize Scale</title>
          <description>Erythema (redness) was assessed.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With no Edema in the Draize Scale</title>
        <description>Edema (swelling) was assessed.</description>
        <time_frame>10 minutes and 30 minutes after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Current Formulation Adalimumab</title>
            <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
          </group>
          <group group_id="O2">
            <title>New Formulation of Adalimumab</title>
            <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With no Edema in the Draize Scale</title>
          <description>Edema (swelling) was assessed.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With no Pruritus in the Draize Scale</title>
        <description>Pruritus (itching) was assessed.</description>
        <time_frame>10 minutes and 30 minutes after injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Current Formulation Adalimumab</title>
            <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
          </group>
          <group group_id="O2">
            <title>New Formulation of Adalimumab</title>
            <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With no Pruritus in the Draize Scale</title>
          <description>Pruritus (itching) was assessed.</description>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                    <measurement group_id="O2" value="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment.</description>
        <time_frame>Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. Serious adverse events were collected from the time that participant signed the informed consent.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Current Formulation Adalimumab</title>
            <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
          </group>
          <group group_id="O2">
            <title>New Formulation of Adalimumab</title>
            <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of study drug administration until 70 days following discontinuation of study drug. In addition, SAEs were collected from the time the participant signed the study-specific informed consent.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Current Formulation Adalimumab</title>
          <description>One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe</description>
        </group>
        <group group_id="E2">
          <title>New Formulation of Adalimumab</title>
          <description>One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

